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Abstract 
Many new strategies for the reconstruction of peripheral nerve injuries have been explored for their effectiveness in 
supporting nerve regeneration. However only a few of these materials were actually clinically evaluated and approved 
for human use. This open, mono-center, non-randomized clinical study summarizes the 12-month follow-up of 
patients receiving reconstruction of the sural nerve biopsy defect by the collagen-based nerve guide Neuromaix. 
Neuromaix was implanted as a micro-structured, two-component scaffold bridging 20–40 mm nerve defects after 
sural nerve biopsy in twenty patients (eighteen evaluated, two lost in follow-up). Safety of the material was evaluated 
by clinical examination of wound healing. Performance was assessed by sensory testing of modalities, pain assess-
ment, and palpation for the Hoffmann–Tinel’s sign as well as demarcating the asensitive area at each follow-up visit. 
Every patient demonstrated uneventful wound healing during the complete 12-month time course of the study. Two 
patients reported complete return of sensation, whereas eleven out of eighteen patients reported a positive Hoff-
mann–Tinel’s sign at the lower leg with simultaneous reduction of the asensitive area by 12 months. Our data show 
that Neuromaix can be implanted safely in humans to bridge sural nerve gaps. No procedure-related, adverse events, 
or severe adverse events were reported. These first clinical data on Neuromaix provide promising perspectives for 
the bridging of larger nerve gaps in combined nerves, which should be investigated more through extensive, multi-
center clinical trials in the near future.
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(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Peripheral nerve injury (PNI) can have devastating con-
sequences for patients when reconstructive strategies 
prove unsatisfactory [1]. Patients not only suffer from the 
functional motor, autonomic, or sensory loss caused by 
the disconnection of the nerve, they often develop sec-
ondary complications of which chronic neuropathic pain 
is the most disabling [2, 3].
In clinical practice the autologous nerve transplanta-
tion (ANT) is still regarded as the clinical gold standard 
to repair complex and extensive nerve injuries [4]. Yet the 
amount of autologous nerve material suitable for trans-
plantation is limited in the human body. To reconstruct, 
most commonly the sensory sural nerve (SN) is har-
vested and implanted to bridge the nerve gap caused by 
the trauma [4]. Moreover harvesting the SN unquestion-
ably leads to functional loss at the donor site, frequently 
followed by secondary complications, such as wound 
healing problems and chronic neuropathic pain [3]. Fre-
quently, the autologous nerve material harvested is not 
sufficient to cover the complete diameter of the damaged 
nerve. Thus even after reconstruction by ANT, functional 
recovery is certainly not guaranteed in each case [1].
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It is therefore not surprising, that in the last decades 
many new strategies and a large number of alternatives 
for the reconstruction of PNI have been explored for 
their effectiveness in supporting nerve regeneration. For 
example, other autologous materials [5–7] (e.g., veins-, 
muscle-, fat-grafts, and processed nerves from human 
corpses), non-degradable [8] (e.g., silicon, or poly-gly-
colic acid), and biodegradable or bio-derived materials 
(e.g., collagen, poly-lactide, chitosan) with micro-guid-
ance structures have been tested pre-clinically for their 
merit in supporting nerve regeneration, most com-
monly in rodent models of PNI [9–18]. However only 
a few of these materials were actually clinically evalu-
ated and approved for human use [19, 20]. From design 
perspective, these materials exist as hollow nerve tubes 
connecting both nerve stumps by an empty tube lumen. 
These materials were most often used for bridging small 
defects in sensory nerves (i.e., most commonly in the 
hand), where they proved to be effective in leading to 
some degree of sensitivity. However the bridging of larger 
nerve defects has remained a challenge. It was suggested 
that for effective bridging, additional microstructures 
within the tube lumen were required [21].
Currently, new strategies aim at developing such 
microstructures using various scaffold designs. For 
example, it was claimed that human donor nerve allo-
grafts retain their connective tissue microstructures and 
are already clinically used to bridge nerve gaps varying 
of 5–50 mm in sensory, motor, and combined nerves [22, 
23]. Twenty-nine out of 42 acute repairs were performed 
in sensory nerves. From these acute repairs, the response 
rate, which was defined as any improvement in quanti-
tative and/or qualitative data investigated, was 92.9%. 
Moreover similar response rates for the repair of sen-
sory branches of the facial nerve have been reported [24]. 
So far this allograft is the only clinically used scaffold to 
our knowledge, providing microstructures to regenerate 
nerves.
The difficulties of translating animal data into the clini-
cal setting have been emphasized lately [25]. Therefore, 
we introduced the medial SN biopsy model to investigate 
newly developed nerve guides in human PNI [20, 25]. In 
the standard procedure, the nerve gap that arises from 
nerve biopsy cannot be reconnected without tension. 
Reconstruction by ANT would be pointless in this case, 
as sensory loss at the donor site would be the trade-off 
[33]. When such an overcritical nerve gap persists, this 
often results in a permanent sensory loss at the lateral 
aspect of the foot. SN biopsies thus provide a very stand-
ardized human nerve injury model to test the biocom-
patibility and regeneration supporting potential of newly 
developed nerve guides [25]. Therefore in this current 
study we implanted the collagen-based, micro-structured 
nerve guide “Neuromaix” into 20–40  mm nerve gaps 
caused by medial SN biopsy in patients. Patients were 
followed until 12 months after surgery. Safety as well as 
performance parameters (i.e., sensory testing of differ-
ent sensory modalities) were quantified for every single 
follow-up visit.
Methods
Screening and patient selection
After obtaining the patients’ written informed con-
sent, a total number of 20 patients, in whom a diagnos-
tic nerve biopsy has been performed, were immediately 
treated with the nerve guide Neuromaix. These patients, 
with a peripheral neuropathy of unclear origin, were 
selected after detailed neurologic history and physical 
examination, nerve conduction studies, and appropri-
ate diagnostic work-up for peripheral neuropathy at the 
Neuromuscular Clinic of the Department of Neurology 
at the RWTH-Aachen University Hospital. Inclusion 
and exclusion criteria for this study are summarized in 
Table 1.
Implantation
All patients were treated with the porcine collagen, 
two-component nerve guide “Neuromaix” (Matricel 
GmbH, Herzogenrath, Germany) that has been pre-
clinically evaluated previously [12–14, 26–31]. Patients 
were operated under local anaesthesia, without seda-
tion as described more detailed recently in Bozkurt 
et  al. [25]. Briefly, patients were lying in prone position 
and an approximately 4–5  cm lazy-S incision was per-
formed along the midline axis of the posterior lower 
leg between the lateral and medial head of the gastroc-
nemius muscle at the musculotendinous transition. The 
medial SN was separated in atraumatic fashion from the 
surrounding tissue by external neurolysis. Meanwhile 
the nerve was flushed with local anaesthetics to alleviate 
possible pain caused by manipulation of the nerve. For 
the nerve biopsy, a 20-mm nerve segment was excised 
and transferred to the Institute of Neuropathology on a 
cotton swab drenched in normal saline solution. Due to 
the relaxation of the nerve ends after the excision, the 
resulting gap size to be bridged by Neuromaix varied 
from 25 to 40 mm. Before implantation, Neuromaix was 
briefly immersed in sterile saline solution, and thereaf-
ter implanted into the nerve gap (Additional file  1: Fig-
ure S1) by using the entubulation technique as described 
previously (for more operational details see [25, 31]). If 
an additional muscle biopsy was required, 1  cm [3] of 
muscle tissue was harvested from the gastrocnemius 
or vastus lateralis muscle (n = 12, Table 3). All patients 
recovered well and responded to be free of post-operative 
pain within 1 week after surgery.
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Follow‑up
After implantation patients were followed for up to 
1  year after operation, with interim follow-up visits at 
1 month, 3, 6, 9, and 12 months after operation (MPO). 
Safety as well as performance parameters were evaluated 
during every follow-up visit and compared to preopera-
tive values and/or values measured on the same day after 
surgery.
Safety was evaluated by yes/no questions to the pres-
ence of typical signs of inflammation (i.e., functional loss, 
redness, swelling, heat, or pain) and to the presence of 
putrid secretion, wound dehiscence, seroma, infection, 
necrosis, or excessive scar tissue formation (hypertrophic 
scarring). If any of these questions was answered posi-
tively, the criterion “uneventful wound healing” was not 
accomplished.
Testing of the different sensory modalities was used to 
evaluate the return of sensation at the lateral aspect of 
the foot as listed in Table 2. To standardize the measuring 
of every follow-up visit, sensory testing (ST) was always 
performed by application of the measuring devices at the 
same, defined measuring point (DMP) located within the 
asensitive area (ASENS) [25].
Hoffmann–Tinel’s Sign
Palpation of the course of the SN was used to detect 
positive Hoffmann–Tinel’s Sign (HTS), a spot that has 
been interpreted as the location of the growth cones of 
regenerating nerve fibers [32, 33]. The patient was asked 
to report, during palpation down the leg, if a spot was 
present located on the lower leg that elicited tingling or 
electrifying sensations perceived at the lateral aspect of 
the foot. This spot or demarcation line was marked as 
the HTS, and distances in relation to the lateral malleo-
lus and middle of the metatarsus five were recorded 
accordingly.
Asensitive area
The area with hypoesthesia was demarcated at every fol-
low-up visit, by asking the patient where sensation was 
experienced as “normal” (i.e., compared to the non-oper-
ated foot) or diminished in response to a non-noxious 
touch stimulus to the ASENS. These areas were photo-
graphed and afterwards the surfaces were measured with 
the freely available Java-based image processing program 
ImageJ (RSB, imagej.nih.gov/ij). Surfaces were expressed 
as a percentage of the area marked on the day of surgery.
Sensory testing
Slight touch sensation was investigated by the application 
of Semmes–Weinstein monofilaments (SWMT) to the 
DMP [34]. The patient was asked whether the filament 
was sensed (yes/no) after every application and slight 
bending of the filament as described previously (Touch 
Test™ Sensory Evaluators, ©Stoelting Co.). The thresh-
old was defined as the filament that was still sensed twice 
during three applications. The 300  g filament was used 
as a cut-off value, and these values include therefore “no 
sensation at all” as well as “sensation at 300 g.”
Pain at the lateral foot was analyzed by self-evaluation 
on a numeric 1–10 VAS scale (NRS), where the score 1 
reflected “no pain at all,” and 10 reflects “the maximal 
imaginable pain.” To verify whether allodynia or other 
pain-related phenomena developed over time at the 
Table 1 In- and exclusion criteria
Inclusion criteria Exclusion criteria
Patients between 18 
and ≤ 70 years
Paraneoplastic pnp
Alcohol-related polyneuropathy 
(pnp)
Current immunosuppressive 
therapy
Malignant tumor
Peripheral vascular disease
Collagenous diseases
Diabetes mellitus
Chronic venous insufficiency
Deep vein thrombosis
Skin diseases in the lower extremity
Coagulopathy or anticoagulant 
therapy
Pregnancy
Infectious diseases (hiv, hepatitis)
Patients with clinical and elec-
trophysiological suspect of a 
peripheral neuropathy that were 
indicated for a nerve biopsy 
to establish the cause of this 
neuropathy
Patients that were mentally and 
legally capable to understand the 
informed consent
Patients that signed the informed 
consent
Table 2 Sensory modalities measured by sensory testing
Sensory modality Test Unit
Hoffmann–Tinel’s Sign Localization of the sign by palpation along the course of the SN cm distance to landmarks and ASENS
Innocuous mechanoreception Tactile: Hypoesthesia (asensitive area, ASENS) cm2
Innocuous mechanoreception Tactile: Semmes–Weinstein Monofilaments g
Innocuous mechanoreception Vibrotactile: vibration at 128 Hz 0–8 scale
Nociception VAS-score, self-evaluation at the lateral foot 1–10 scale
Nociception Presence of touch-hypersensitivity at the lateral foot Yes/no
Spatial distribution Pointed (sharp)/blunt discrimination Yes/no
Thermoception Cold/warm discrimination Yes/no
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lateral aspect of the foot, the patient was asked if touch 
of the ASENS elicited any pain sensation, and if so, to 
describe this sensation.
Vibrotactile sensation was determined by application of 
a 128  Hz tuning fork containing a 0–8 scale (Aesculap, 
Braun). The fork was activated and placed on the DMP, 
where after the patient was asked to announce when 
vibration was not sensed anymore. At this point, the 
value depicted by two intersecting triangles on the 0–8 
scale was noted as previously described [35].
Spatial distribution was evaluated by responding to 
sharp or blunt stimuli. The patient was asked to respond 
to application of a 10 g (i.e., filament 5.07 in the SWMT) 
monofilament to the DMP. A positive blunt or sharp-
sensation response was valued as an immediate response 
after application of the device to the DMP, when two 
out of three applications were correctly answered as 
being blunt or sharp  (Neuropen®, Owen Mumford, 
Freudenberg).
Cold sensation was evaluated by asking the patient to 
respond to the application of a metal (cold) or a plastic 
(in comparison, warm) element of the Tip therm device. 
A positive cold-sensation response was valued as an 
immediate response after application of the device to the 
DMP, when two out of three applications were correctly 
classified as being cold or warm (Tip  Therm®, Tip Therm 
GmbH).
Statistical analyses
For the performance part of the study, two cases were 
excluded because of incomplete follow-up, and as a con-
sequence the datasets of a total of 18 patients were used 
for evaluation. The non-operated side served as an intra-
individual control, whereas preoperative values were 
used to compare the course of sensory regain in time in 
relation to preoperative values.
Indeed values were tested for equal variances and 
normality prior to statistical testing. However, due to 
Table 3 Demographic data
Patient Gender Age Clinical diagnosis Muscle biopsied Pathological diagnose
1 M 54 Sensorimotor PNP – Chronic neuritis, axonal neuropathy
2 F 69 Sensory PNP – Undefined, CIDP, or neoplasm excluded
3* F 63 Sensorimotor PNP GN Chronic axonal neuropathy with neurogenic muscle atrophy
4 M 48 Sensory PNP GN Chronic, partially axonal, and demyelinating neuropathy with muscle atrophy
5 M 50 Sensorimotor PNP – Chronic, partially axonal, and demyelinating neuropathy
6 M 57 Sensory PNP GN Chronic, axonal neuropathy, neurogenic muscle atrophy, and perivascular inflam-
matory cell infiltrates in the muscle
7 M 67 Sensory PNP VL Chronic, predominantly axonal neuropathy with moderate demyelinating compo-
nents, micro-angiopathy of endo- and epineural blood vessels, chronic neuro-
genic muscle atrophy, neuritis, and vasculitis-excluded, possible hereditary PNP
8 M 43 Sensory PNP GN Chronic, predominantly demyelinating neuropathy with axonal components, 
chronic neurogenic muscle atrophy, mitochondrial abnormalities
9 M 53 Sensorimotor PNP GN Chronic, predominantly axonal neuropathy with demyelinating components, 
neurogenic muscle atrophy
10* M 46 Sensorimotor PNP GN Chronic, predominantly axonal neuropathy with demyelinating components, 
neurogenic muscle atrophy
11 M 65 Cidp – Chronic axonal and demyelinating neuropathy micro-angiopathy of endo- and 
epineural blood vessels
12 M 48 Sensory PNP GN Chronic axonal neuropathy with demyelinating components, micro-angiopathy of 
endo- and epineural blood vessels, chronic neurogenic muscle atrophy
13 M 54 Motoric PNP GN Chronic, axonal neuropathy, chronic neurogenic muscle atrophy
14 F 61 Sensory PNP VL Chronic, predominantly axonal neuropathy, with little demyelinating components, 
micro-angiopathy of endoneurial blood vessels, progressive neurogenic muscle 
atrophy
15 M 46 Sensorimotor PNP – Chronic, axonal neuropathy of demyelinating hypertrophic type
16 M 41 Sensorimotor PNP GN Chronic, axonal neuropathy, chronic neurogenic muscle atrophy
17 F 55 Sensory PNP – Chronic, axonal neuropathy, micro-angiopathy of endo- and epineural blood ves-
sels, no neuritis
18 F 53 Sensorimotor PNP – Chronic, axonal neuropathy
19 M 39 Sensorimotor PNP GN Chronic, axonal neuropathy with demyelinating components, endoneurial inflam-
matory cell infiltrates, neurogenic muscle atrophy
20 F 47 Sensory PNP – Chronic, predominantly axonal neuropathy with few components, possible neuritis
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the small N-number, only non-parametrical tests were 
performed. Comparison between operated and non-
operated values was done by two-way ANOVA repeated 
measures with Bonferroni post hoc testing, whereas the 
comparison between the different time points within 
one side (operated vs non-operated) was performed by 
Kruskal–Wallis testing, with Dunn’s multiple comparison 
post hoc testing.
All graphs represent mean with standard error of the 
mean (SEM), and p values below 0.05 were considered as 
statistically significant. Statistical analysis was performed 
with GraphPad Prism 5 software (GraphPad Software, 
San Diego, CA, USA).
Results
Twenty-three patients were screened according to the 
in- and exclusion criteria listed in Table 1. Three patients 
did not fulfill the criteria for implantation. Finally Neuro-
maix was implanted in a total of 20 patients after medial 
SN biopsy. These patients consisted of 6 female and 14 
male individuals, with a mean age of 52 years ± 1.9 and 
ranging from 39 to 69 years. In twelve patients additional 
muscle biopsies (gastrocnemius, n  =  10 and/or vastus 
lateralis, n  =  2) were simultaneously performed. Dur-
ing the course of the study, one non-study-related severe 
adverse event (SAE) and three non-study-related adverse 
events (AE) were reported. No procedure-related, AE 
or SAE occurred. Two patients were lost in follow-up 
(Patient 003 and 010, marked with * in Table 3). Hence, 
for the evaluation of performance 18 datasets were 
included in the analysis; however, safety was evaluated 
for all 20 patients.
The first follow-up visit occurred at 1  month after 
operation (MPO). All patients investigated in this current 
study demonstrated clear wound healing during the com-
plete follow-up period. Figure 1 demonstrates represent-
ative images at one, three, and 6  months after surgery. 
Patients did not report foreign body sensations caused by 
the implanted material. In addition, except for 2–3 days 
post-operative pain around the area of incision, they were 
pain-free within 1 week after surgery.
Prerequisite for including the patient’s dataset into the 
performance analysis was to rule out that the patient’s 
underlying disease may not allow formation of new 
sprouts. Hence, neuropathological examination of the 
biopsied nerve samples was used to distinguish whether 
newly formed axonal sprouts were present in the nerve 
tissue. All patients demonstrated clusters of regenerating 
nerve fibers in the histological preparations, indicative of 
an intrinsic ability of the nerve fibers to form new sprouts 
that may regenerate (Additional file 2: Figure S2).
Representative examples of the wandering HTS in time 
are shown in Fig.  2a–c. Nine months after surgery, the 
HTS was detected as a sensitive, electrifying spot on the 
lower leg. Three months later this spot could be detected 
at the level of the lateral malleolus.
A positive HTS below the complete operation area was 
first detectable at 6 MPO in 2/18 patients (11%). Thereaf-
ter the percentage of patients with a positive HTS at the 
lower leg increased to 10/18 (56% at 9 MPO) and 15/18 
(83% at 12 MPO). From these 15 patients with a positive 
HTS below the operation area, 11 showed simultaneously 
a reduction in the ASENS. Five of these 11 reported a 
HTS located below the lateral malleolus (28%, data points 
above the dotted 100% line in Fig. 2d). Immediately after 
surgery and at 1 MPO, the majority of patients reported 
complete numbness at the ASENS. Thereafter some 
degree of (protective) touch sensation developed over 
time, but often patients described a different sensation 
when compared to the non-operated side (i.e., most com-
monly described as: “delayed sensation” and/or “sensa-
tion as being covered under an asensitive layer”). ASENS 
did change in time in individual patients, but mean val-
ues during the 12-month follow-up did not statistically 
significantly differ from the status immediately after sur-
gery (Fig.  2e). Two patients who reported a clear HTS 
Fig. 1 Representative example of wound healing after Neuromaix implantation. Clear wound healing was evident already after 1 month after 
biopsy and Neuromaix implantation (a). At 3 (b) and 6  months (c) and also thereafter no complications could be observed in any of the patients 
(Example of patient 17)
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at 9 MPO did not sense a positive HTS at 12 MPO any-
more, which coincided with the recurrence of full sensa-
tion within the ASENS.
Figure 3 demonstrates in a–c examples of the ASENS 
in relation to the location of the positive HTS 1  month 
after surgery, whereas  a*–c* shows a smaller ASENS at 
12 MPO. In addition, Fig. 3a**, b**, c** visualizes the dis-
tance traversed by the HTS in relation to the ASENS at 
12 MPO (Red circles show the location of the HTS and 
yellow arrows the location of the middle of the scar, 
respectively).
Prior to operation, mechanical sensation at both 
feet was similar (operated, open circles: 3.8 ±  0.3, non-
operated, filled squares: 3.8  ±  0.2, Fig.  4a). After the 
operation, a clear elevation of the mechanical sensitivity 
threshold could be observed at the operated foot when 
compared to the non-operated side (operated: 5.8 ± 0.4, 
non-operated: 3.8 ± 0.2, ***p < 0.001). Immediately after 
surgery, thresholds were in the range of “loss of protective 
sensation.” At this time point, patients often responded 
with “no sensation at all” (53%, deep pressure sensation 
only). This post-operative elevation of the mechani-
cal sensitivity threshold faded in time, but thresholds 
remained higher than compared to the non-operated side 
(Fig. 4a, **p < 0.01 at 3 and 9 MPO and at 12 MPO; oper-
ated: 4.5 ± 0.3 open circles, non-operated 3.5 ± 0.2, filled 
squares *p < 0.05). This coincided with patients reporting 
return of protective sensation (i.e., complete numbness 
changed into some degree of touch sensation).
Patients displayed post-operative pain around the opera-
tion site during the first 2  days after surgery, but after 
1  week, patients were completely free of any pain. Over 
time patients did not show strong fluctuations in pain 
sensation at the lateral foot (Fig.  4b). VAS scores prior 
Fig. 2 Traversing of the positive HTS in time and measurements of the ASENS. Six months after surgery a positive HTS was detected at the lower 
leg approximately 15 cm above the Achilles tendon (a). After 9 months this spot was detected more distally at approximately 10 cm distant from 
the Achilles tendon (b). Three months later this spot was detected at the level of the lateral malleolus (c) (Images of patient 2). Positive HTS below 
the operation site in the majority of patients could be observed as early as 9 months after surgery. Thereafter, the number of patients who reported 
positive HTS increased as well as the distance traversed by the wandering HTS. By 12 MPO, fifteen patients demonstrated a positive HTS below the 
operation site. Eleven of them demonstrated simultaneously a reduction in the ASENS and five patients of this latter population showed a positive 
HTS located below the lateral malleolus. Two patients reported no sensation of a HTS anymore, but reported complete recovery of sensation at the 
lateral aspect of the foot (dotted line represents HTS located at the lateral malleolus = 100%, below this line < 100% heading towards, and above 
this line > 100% HTS located below the lateral malleolus) (d). Quantification of the mean ASENS in patients with a positive HTS as percentage of the 
area immediately after surgery (e)
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to surgery were slightly elevated for the operated side 
(5.2 ± 0.7, open circles) when compared to the non-oper-
ated side (4.0 ± 0.8, *p > 0.05, filled squares). None of the 
patients reported pain, but rather reported numbness, or 
tingling sensations after touch of the ASENS. Immediately 
after surgery, a drop in vibration sensation (Fig. 4c) could 
be observed at the operated side compared to the preop-
erative status, but this reduction was not statistically sig-
nificant (preoperative: 5.1  ±  0.8 and 0 MPO: 2.4  ±  0.9). 
Vibration sensation returned (12 MPO: operated: 5.0 ± 0.6, 
open circles), but remained slightly lower than at the non-
operated side (12 MPO: 5.7 ± 0.4, filled squares).
Figure 4d demonstrates the percentage of patients that 
perceived blunt stimuli (10  gr SWT filament) in time. 
Blunt sensation returned quite rapidly after surgery, as 
with 1 MPO approximately halve of the patients (56%) 
sensed the 10 g SWT filament. After 12 MPO, this per-
centage was increased to 83%. Sharp sensation (pin-
prick) did not recover as quickly as blunt sensation after 
surgery; up to 9 MPO less than half of the patients were 
able to detect the sharp stimulus (33%). During the last 
3 months, a clear recovery could be observed, as finally 
at 12 MPO 61% of the patients were able to detect sharp 
stimuli (Fig.  4e). The number of patients who detected 
the cold stimulus increased only little in time. Even after 
12 MPO the majority of patients were unable to detect 
cold stimuli (33% Fig. 4f ).
Discussion
To date there is still an urgent clinical request for alterna-
tives to the autologous nerve transplantation for the repair 
of damaged peripheral nerves [1–3]. These alternatives 
Fig. 3 Example images of patients that showed reduction in the ASENS as well as a positive HTS that was found in the vicinity of the lateral malleo-
lus. ASENS 1 month after surgery (a–c). Reduced ASENS at 12 MPO (a*–c*). The distance traversed by the HTS in relation to the ASENS at 12 MPO. 
Red circles indicate the location of the HTS, whereas the yellow arrows indicate the middle of the scar at the level of the calf (a**–c**) (Images of 
patient 8, 9, and 13)
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can exist of biomaterials having the advantage that they 
can be used off the shelf. In this present study we evalu-
ated the newly developed collagen-based nerve guide 
Neuromaix in a first in human study. As a two-compo-
nent scaffold, Neuromaix was implanted into 20–40 mm 
sural nerve biopsy defects to support functional axonal 
regeneration across this nerve gap [25]. Safety as well as 
performance parameters of this application of the scaffold 
were evaluated up to 1 year after the implantation.
Our data first of all show that Neuromaix is safe; 
uneventful wound healing was evident in every patient 
during the complete follow-up of this study. Our findings 
are in line with previous reports about collagen materi-
als being well tolerated by the human body, in general 
[36] and more specifically after implantation as a tube 
in human PNI [37]. Moreover, our own findings for 
Neuromaix in animal experiments of PNI complement 
these current first in human results [12–14, 26–31]. In 
addition, patients did not complain about foreign body 
sensations caused by the material. Except for a few days 
post-operative pain (maximally 1 week), patients did not 
develop any persistent pain around the scar area or at 
Fig. 4 Mechanical sensation was reduced immediately after the operation, and patients often reported “no sensation at all.” Thereafter mechanical 
sensitivity thresholds slightly improved, but never reached values measured at the non-operated side (a). VAS scores remained constant over time 
on both non-operated and operated feet (b). Vibrotactile sensation was slightly reduced after surgery (ns). In time, vibrotactile sensation recovered, 
but remained reduced compared to the non-operated foot (c). Blunt sensation returned quite rapid after surgery; by 1 MPO slight touch with the 
10 g filament elicited in more than 50% of the patients a positive response (d). Sharp sensation recovered slower; only in the last month there was a 
clear improvement in the majority of patients detectable (e). Cold sensation showed a slower recovery in time, and even after 12 MPO the majority 
of patients were unable to sense the cold metal tip (f). Data of a–c represent mean ± SEM where */**/*** represent p < 0.05/0.01/0.001 operated vs 
non-operated, ### represents p < 0.001 preoperative vs post-surgery, + represents p < 0.05 post-surgery compared to immediately after surgery (0 
MPO). Graphs d–f represent percentages of total
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the lateral foot. Most commonly sensation after touch at 
the ASENS was described as “delayed” or “covered by an 
asensitive layer” hypoesthesia, but never as painful to a 
non-painful stimulus (mechanical allodynia), or as burn-
ing or stinging pain (hyperalgesia).
Second, our data support the notion that implantation 
of Neuromaix may serve as a standard repair method to 
overcome secondary complications after nerve biopsy 
[37–41]. Biopsy removal at the level of the calf, in com-
parison to the classical method at the lateral malleolus 
[39], provides, as our data confirm, ideal wound heal-
ing conditions with excellent soft tissue covering. This 
method provides the opportunity to obtain muscle biop-
sies at the same time, without losing diagnostic value of 
the biopsies taken [42, 43] and providing the most opti-
mal wound healing conditions for the patient, as already 
discussed previously [25]. In addition, the majority of the 
patients reported spontaneous tingling and electrifying 
sensations, which has been associated with movement 
of the growth cone, but no pain between follow-up visits 
[32, 33].
The nerve’s intrinsic ability to regenerate is, of course, 
a prerequisite for the evaluation of performance. Patients 
assigned for a nerve biopsy concern a population that has 
already been examined clinically by the standard diag-
nostic work-up for PNP, showing no abnormalities in 
blood/spinal fluid counts, though often demonstrating 
abnormal electrophysiological parameters (i.e., impaired 
amplitudes and motor/sensory nerve conductance veloc-
ities). By semi-thin resin section histology of the biopsy 
material, we confirmed the presence of regeneration clus-
ters in every patient, indicating the intrinsic capability of 
the nerve to regenerate. Thus, all patients with complete 
follow-up could be included into the performance analy-
sis (n = 18). However, we noticed by tracking the HTS in 
time that regeneration rates in our patients were slower 
than the 1  mm/day frequently reported in literature for 
healthy persons [44]. Our data confirm that the patient’s 
underlying disease condition is an important factor influ-
encing nerve regeneration [45]. Therefore the patient’s 
underlying condition should be taken into account all 
time while planning and evaluating data in this nerve 
injury model, as it has an important influence on regen-
eration and the timing of the return of sensation.
Moreover another important factor in our study to 
consider is the age of our patient population (mean age 
52 years ± 1.9, range 39–69 years). Previous work from 
others already showed that age is an important factor 
influencing myelin- and axonal-related parameters, the 
proportions of different fiber types in the nerve, and elec-
trophysiological properties (Summarized in Verdu 2000 
[45]). It can be expected that variability in age may also 
account for the individual differences observed in our 
patients with regard to the timing and degree of return-
ing of sensation.
Indeed biopsy and implantation at the level of the calf 
is located more distant from the target organ than at 
the ankle [37–41], and therefore regenerating nerve fib-
ers have to traverse a longer distance to re-innervate the 
lateral skin of the foot. It can be expected that this has 
also implications for the timing of return of sensation. 
However, we were able to detect positive HTS in fifteen 
out of eighteen patients by 12 MPO. Moreover eleven of 
them demonstrated a HTS below the operation area with 
simultaneous reduction in the ASENS, suggesting that 
nerve fibers once regenerated across Neuromaix, entered 
the former trajectories of the SN [32, 33]. Five of the lat-
ter demonstrated positive HTS that passed the lateral 
malleolus heading towards the lateral aspect of the foot 
and two of them reported complete return of sensation 
by 12 MPO.
All patients reported reduced sensation in the area 
innervated by the SN immediately after operation. This 
was confirmed by the testing of various sensory modali-
ties. Some degree of protective touch sensation returned 
in all patients. Sharp and cold sensation recovered more 
slowly than touch and vibration sensation. As previously 
mentioned, timing of the return of sensation has been 
shown to depend on age, gender, underlying disease of 
the patient, time to repair and the type, location, and 
extend of injury [46]. This may partly account for the 
individual differences in recovery seen in our population 
(i.e., here influenced by age, gender, and underlying dis-
ease). With respect to the different sensory modalities, 
thresholds generally increase during aging [45]. Compar-
ison to other repair approaches is difficult, as the timing 
of, and the extent of sensory regain highly depends on the 
size of the nerve gap to be bridged (i.e., < 15 mm or over-
critical), the distance to be traversed by the regenerating 
axons (i.e., distant or near the target skin areal) as well 
as the location of the area to be re-innervated (i.e., hand 
palms/foot soles, or dorsolateral foot). For the lower 
extremities, the greatest alterations in sensation after 
PNI have been reported to manifest as loss of mechani-
cal pressure, vibration, and cold detection [47]. Hyperes-
thesia as well as hyperalgesia were less frequently seen. 
In addition pain-related symptoms were detected with 
reduced thresholds to cold and pressure pain. In contrast, 
warm pain sensation showed elevated thresholds [47]. 
Loss of touch, vibration, and cold sensation was also evi-
dent in our patient population after surgery, but steadily 
improved over time.
Eleven of fifteen patients with a positive HTS at the 
lower leg demonstrated simultaneously a reduction in 
the ASENS, suggesting that newly regenerated fibers 
re-innervated the skin areal of the lateral foot. As these 
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observations were not concurred by pain-related symp-
toms at the ASENS, implantation of Neuromaix could 
become a standard procedure after nerve biopsy to over-
come possible co-morbidities. Restoration the transmis-
sion of sensory information from the periphery to the 
brain has been suggested to alleviate pain-related symp-
toms, such as allodynia [48, 49]. This method can even 
be extrapolated to conditions where harvesting of donor 
nerve material for transplantation leaves a nerve gap.
Electrophysiological recordings and neuro-imaging 
techniques however are needed to complement these first 
results on sensory regain [50, 51]. Nevertheless, our data 
provide promising prospective for the reconstruction of 
combined nerves, which should be tested in larger, rand-
omized, multi-center, clinical trials in the near future.
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